Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1993 1
2000 1
2009 1
2017 1
2018 4
2019 1
2021 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, Tardif JC, Ballantyne CM; REDUCE-IT Investigators. Bhatt DL, et al. N Engl J Med. 2019 Jan 3;380(1):11-22. doi: 10.1056/NEJMoa1812792. Epub 2018 Nov 10. N Engl J Med. 2019. PMID: 30415628 Clinical Trial.
METHODS: We performed a multicenter, randomized, double-blind, placebo-controlled trial involving patients with established cardiovascular disease or with diabetes and other risk factors, who had been receiving statin therapy and who had a fasting triglyceride level of 135 to 499 …
METHODS: We performed a multicenter, randomized, double-blind, placebo-controlled trial involving patients with established cardiovascular d …
Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly.
McNeil JJ, Wolfe R, Woods RL, Tonkin AM, Donnan GA, Nelson MR, Reid CM, Lockery JE, Kirpach B, Storey E, Shah RC, Williamson JD, Margolis KL, Ernst ME, Abhayaratna WP, Stocks N, Fitzgerald SM, Orchard SG, Trevaks RE, Beilin LJ, Johnston CI, Ryan J, Radziszewska B, Jelinek M, Malik M, Eaton CB, Brauer D, Cloud G, Wood EM, Mahady SE, Satterfield S, Grimm R, Murray AM; ASPREE Investigator Group. McNeil JJ, et al. N Engl J Med. 2018 Oct 18;379(16):1509-1518. doi: 10.1056/NEJMoa1805819. Epub 2018 Sep 16. N Engl J Med. 2018. PMID: 30221597 Free PMC article. Clinical Trial.
Effect of Aspirin on All-Cause Mortality in the Healthy Elderly.
McNeil JJ, Nelson MR, Woods RL, Lockery JE, Wolfe R, Reid CM, Kirpach B, Shah RC, Ives DG, Storey E, Ryan J, Tonkin AM, Newman AB, Williamson JD, Margolis KL, Ernst ME, Abhayaratna WP, Stocks N, Fitzgerald SM, Orchard SG, Trevaks RE, Beilin LJ, Donnan GA, Gibbs P, Johnston CI, Radziszewska B, Grimm R, Murray AM; ASPREE Investigator Group. McNeil JJ, et al. N Engl J Med. 2018 Oct 18;379(16):1519-1528. doi: 10.1056/NEJMoa1803955. Epub 2018 Sep 16. N Engl J Med. 2018. PMID: 30221595 Free PMC article. Clinical Trial.
Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG.
Verma S, Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Dhingra NK, Ketchum SB, Juliano RA, Jiao L, Doyle RT Jr, Granowitz C, Gibson CM, Pinto D, Giugliano RP, Budoff MJ, Mason RP, Tardif JC, Ballantyne CM; REDUCE-IT Investigators. Verma S, et al. Circulation. 2021 Dec 7;144(23):1845-1855. doi: 10.1161/CIRCULATIONAHA.121.056290. Epub 2021 Oct 28. Circulation. 2021. PMID: 34710343 Free article. Clinical Trial.
METHODS: In REDUCE-IT (Reduction of Cardiovascular Events With Icosapent Ethyl-Intervention Trial), a multicenter, placebo-controlled, double-blind trial, statin-treated patients with controlled low-density lipoprotein cholesterol and mild to moderate hypertriglyceridemia were ra …
METHODS: In REDUCE-IT (Reduction of Cardiovascular Events With Icosapent Ethyl-Intervention Trial), a multicenter, placebo-controlled, doubl …
Effect of Aspirin on Disability-free Survival in the Healthy Elderly.
McNeil JJ, Woods RL, Nelson MR, Reid CM, Kirpach B, Wolfe R, Storey E, Shah RC, Lockery JE, Tonkin AM, Newman AB, Williamson JD, Margolis KL, Ernst ME, Abhayaratna WP, Stocks N, Fitzgerald SM, Orchard SG, Trevaks RE, Beilin LJ, Donnan GA, Gibbs P, Johnston CI, Ryan J, Radziszewska B, Grimm R, Murray AM; ASPREE Investigator Group. McNeil JJ, et al. N Engl J Med. 2018 Oct 18;379(16):1499-1508. doi: 10.1056/NEJMoa1800722. Epub 2018 Sep 16. N Engl J Med. 2018. PMID: 30221596 Free PMC article. Clinical Trial.
Rapid Onset of Ceftriaxone-Induced Cholelithiasis in an Adult Patient.
Abdelaziz H, Cormier N, Levesque T, St-Yves J, Habash MA, Diaz O, Haberer MP, Calugaroiu D, Nashed M. Abdelaziz H, et al. J Glob Infect Dis. 2022 Feb 16;14(1):31-34. doi: 10.4103/jgid.jgid_11_21. eCollection 2022 Jan-Mar. J Glob Infect Dis. 2022. PMID: 35418730 Free PMC article.
A 57-year-old female was admitted to our hospital for meningitis and treated empirically with ceftriaxone 2 g every 12 hours. Other medications given included vancomycin, ampicillin and acyclovir. ...Ceftriaxone was discontinued and switched to cefotaxime 2 g every …
A 57-year-old female was admitted to our hospital for meningitis and treated empirically with ceftriaxone 2 g every 12 hours. Other m …
Evaluation of a possible role for antimutagens, antiteratogens, and anticarcinogens in reducing environmental health hazards.
Nashed N. Nashed N. Environ Health Perspect. 1976 Apr;14:193-200. doi: 10.1289/ehp.7614193. Environ Health Perspect. 1976. PMID: 789065 Free PMC article. Review.
The use of protective agents (e.g., sulfhydryl compounds, certain vitamins, amino acids, cations, and antibiotics) offers a novel and promising means of dealing with the ever increasing burden of environmental hazards facing man. Through the daily uptake of minimal doses a …
The use of protective agents (e.g., sulfhydryl compounds, certain vitamins, amino acids, cations, and antibiotics) offers a novel and …
Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients.
Ridker PM, Revkin J, Amarenco P, Brunell R, Curto M, Civeira F, Flather M, Glynn RJ, Gregoire J, Jukema JW, Karpov Y, Kastelein JJP, Koenig W, Lorenzatti A, Manga P, Masiukiewicz U, Miller M, Mosterd A, Murin J, Nicolau JC, Nissen S, Ponikowski P, Santos RD, Schwartz PF, Soran H, White H, Wright RS, Vrablik M, Yunis C, Shear CL, Tardif JC; SPIRE Cardiovascular Outcome Investigators. Ridker PM, et al. N Engl J Med. 2017 Apr 20;376(16):1527-1539. doi: 10.1056/NEJMoa1701488. Epub 2017 Mar 17. N Engl J Med. 2017. PMID: 28304242 Free article. Clinical Trial.
Spectrofluorimetric method for measuring the activity of the enzyme alpha-L-fucosidase using the ion associate of 2-chloro-4-nitro phenol-rhodamine-B.
El-Shahawi MS, Othman AM, El-Houseini ME, Nashed B, Elsofy MS. El-Shahawi MS, et al. Talanta. 2009 Nov 15;80(1):19-23. doi: 10.1016/j.talanta.2009.04.070. Epub 2009 Jun 11. Talanta. 2009. PMID: 19782187
A low cost and accurate method for the detection and analytical determination of the activity of the enzyme alpha-L-fucosidase (AFU) was developed. The method was based upon measuring the fluorescence intensity of the complex ion associate of the ion associate of rhodamine …
A low cost and accurate method for the detection and analytical determination of the activity of the enzyme alpha-L-fucosidase (AFU) …
Binding of the O-antigen of Shigella dysenteriae type 1 and 26 related synthetic fragments to a monoclonal IgM antibody.
Pavliak V, Nashed EM, Pozsgay V, Kovác P, Karpas A, Chu C, Schneerson R, Robbins JB, Glaudemans CP. Pavliak V, et al. J Biol Chem. 1993 Dec 5;268(34):25797-802. J Biol Chem. 1993. PMID: 7503987 Free article.
Shigella dysenteriae type 1 possesses an O-antigen whose repeating unit is -->3)-alpha-L-Rhap-(1-->3)-alpha-L-Rhap-(1-->2)-alpha-D-Galp -(1-->3)-alpha-D- GlcpNAc-(1-->, where Rhap is rhamnopyranosyl, Galp is galactopyranosyl, and Glcp is glucopyranosy …
Shigella dysenteriae type 1 possesses an O-antigen whose repeating unit is -->3)-alpha-L-Rhap-(1-->3)-alpha-L-Rhap-(1--& …
11 results